Research progress in targeted therapy of non small cell lung cancer
Objective To investigate the clinical effect of targeted drug therapy for non-small cell lung cancer.MethodsThe study group received gefitinib targeted drug therapy, the control group was given erlotinib treatment, recording two groups of patients with non-small cell lung cancer, survival time, follow-up treatment costs and adverse reaction incidence (drug).ResultsThe total efficiency of treatment (37.50%) and the control group (the total efficiency of treatment 35.42%) no obvious difference;no significant difference between the survival time of patients in group two non-small cell lung cancer, but the study group treatment costs significantly less than the control group (P<0.05);two groups of patients with non-small cell lung cancer were treated with erlotinib and gefitinib poisoning reaction contrast did not significant difference.ConclusionGefinitib targeted therapy of non-small cell lung cancer can be based on protecting the clinical curative effect and prognosis of the patients, reduce the economic pressure, more conducive to the positive reception and treatment.
non small cell lung cancertargeted drugtherapeutic effect
NETL
NSTL
万方数据
维普
